Understanding interactions like EGF‐EGFR's influence on PD‐L1 is especially relevant given the ongoing clinical trials assessing the use of afatinib (EGFR‐TKI) in advanced BC (NCT02122172). This evidence concerns the gene CD274 and breast cancer.